Edwards EVOQUE Transcatheter Tricuspid Valve Replacement System
Edwards Lifesciences, LLC · Decision date Aug 13, 2025
What did the FDA approve?
FDA records P230013/S016 as a supplement to PMA P230013, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Aug 13, 2025.
FDA approval order statement
approval to add the Edwards Singapore facility, located in Changi, Singapore, as a qualified manufacturing site for the EVOQUE valve component of the EVOQUE TTVR System
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Aug 13, 2025
- FDA change category
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P230013/S016
- Regulatory pathway
- PMA supplement
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPW
- Decision code
- APPR
- Decision date
- Aug 13, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneously Delivered Prostheses and Tricuspid Valves.
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230013. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230013 · Original PMA
Edwards EVOQUE Tricuspid Valve Replacement System
P230013/S016 received
Application receipt date recorded by FDA.
P230013/S017 · Related supplement
Edwards EVOQUE tricuspid delivery system
P230013/S016 · FDA decision
Normal 180 Day Track No User Fee
P230013/S018 · Related supplement
Edwards EVOQUE tricuspid delivery system
P230013/S020 · Related supplement
Edwards EVOQUE Tricuspid Valve Replacement System
P230013/S013 · Related supplement
Edwards EVOQUE Tricuspid Valve Replacement System
P230013/S019 · Related supplement
EVOQUE Tricuspid Valve Replacement System
P230013/S021 · Related supplement
Edwards EVOQUE Tricuspid Valve Replacement System
P230013/S022 · Related supplement
Edwards EVOQUE Loading System (9850LSA); Edwards EVOQUE Loading System and Trimmer (9850LSB)
P230013/S023 · Related supplement
Edwards EVOQUE Tricuspid Valve Replacement System (9850TDS)
P230013/S024 · Related supplement
Edwards EVOQUE Heart Valve (sizes 44mm, 46mm, 48mm, 52mm)
P230013/S025 · Related supplement
Edwards EVOQUE Tricuspid Valve Replacement System
P230013/S026 · Related supplement
EVOQUE Tricuspid Valve Replacement System
P230013/S028 · Related supplement
Edwards EVOQUE Loading System and Trimmer, Model 9850LSB
P230013/S030 · Related supplement
Edwards EVOQUE Tricuspid Valve Replacement System
P230013/S031 · Related supplement
EVOQUE Tricuspid Delivery System (9850TDS); EVOQUE dilator kit (9850DK)
P230013/S032 · Related supplement
Edwards EVOQUE Tricuspid Valve Replacement System
P230013/S027 · Related supplement
EVOQUE Tricuspid Valve Replacement System
P230013/S029 · Related supplement
Edwards EVOQUE Tricuspid Valve Replacement System
P230013/S033 · Related supplement
EVOQUE Tricuspid Valve Replacement System
P230013/S034 · Related supplement
Edwards EVOQUE Tricuspid Valve Replacement System (9850EV)
Timeline entries are records held by MedtechLedger for P230013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230013
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Edwards Lifesciences, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- One Edwards Way, Irvine, CA, 92614
Sources and methodology
- Original FDA record: P230013/S016
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


